Viralgen and Elaaj Bio Join Forces to Enhance Gene Therapy for CDKL5 Deficiency Disorder

Viralgen and Elaaj Bio Unite for Revolutionary Gene Therapy Program

In a groundbreaking move within the biotech landscape, Viralgen, a renowned contract development and manufacturing organization (CDMO), has announced its partnership with Elaaj Bio, an innovative biotechnology firm. The collaboration aims to further develop gene therapy for CDKL5 deficiency disorder, a rare neurological condition affecting children. This partnership symbolizes a significant step forward in the fight against CDKL5 deficiency, characterized by severe developmental and epileptic challenges.

Collaborative Approach to Gene Therapy

Viralgen is leveraging its extensive experience in developing recombinant adeno-associated virus (rAAV) vectors to spearhead the preclinical gene therapy program tailored for CDKL5 deficiency. This strategic alliance combines Viralgen's advanced manufacturing capabilities with Elaaj Bio's commitment to creating groundbreaking treatments for this devastating disorder.

The complexity of gene therapy, particularly for rare pediatric diseases, calls for such partnerships to streamline development processes and bolster resource allocation. As Jimmy Vanhove, CEO of Viralgen, aptly stated, “Collaborations like this are essential for progressing complex gene therapy programs, especially in rare pediatric diseases where there is a high demand for innovative therapies.”

The Impact of CDKL5 Deficiency Disorder

CDKL5 deficiency disorder (CDD) is a severe form of epilepsy that impairs cognitive and motor skills in affected children. Symptoms typically arise early in life, including frequent seizures and notable neurodevelopmental delays that drastically affect the quality of life for both patients and their families. The goal of the ongoing research is to address the genetic root cause of the disorder through a targeted gene therapy approach.

Elaaj Bio is wholly owned by the Loulou Foundation, a non-profit organization dedicated to advancing research for CDKL5. As Russ Addis, the head of development strategy and genetic medicine at the Loulou Foundation, highlighted, the commitment to finding effective treatments is paramount. The alliance with Viralgen reaffirms this mission, bolstering hope for a future where effective therapies can mitigate the effects of CDKL5 deficiency.

Development and Production Plans

Under the collaboration, Viralgen will utilize its state-of-the-art facilities and technologies to support critical development activities. These include optimizing production processes, scaling manufacturing capacity, thorough analytical characterization, and stringent quality control measures. Initial development efforts have shown favorable results, proving the technical feasibility of the manufacturing approach. Current activities focus on scaling up processes to support the upcoming clinical trials.

The first clinical trial for the gene therapy program, designated ELJ-101, is slated to launch in early 2027. As exciting advancements unfold, both organizations remain deeply committed to ensuring high standards in their manufacturing and development practices.

About Viralgen and Elaaj Bio

Founded in 2017 as a subsidiary of AskBio, Inc. within Bayer AG, Viralgen has become a leader in AAV-based gene therapy manufacturing. Situated in San Sebastián, Spain, the company offers comprehensive services from early development to large-scale commercial production. With a proprietary Pro10™ suspension cell line and Aava™ manufacturing platform, Viralgen is equipped for high-yield production of all AAV serotypes.

Elaaj Bio, wholly owned by the Loulou Foundation, drives research projects aimed at unraveling the complexities of the CDKL5 disorder. The foundation is responsible for funding numerous studies in top-tier institutions across the United States and Europe, and hosts annual meetings that bring together experts in the field to share insights and collaborate on future endeavors.

As the partnership between Viralgen and Elaaj Bio progresses, the hope is that their joint efforts will lead to significant breakthroughs in the treatment of CDKL5 deficiency disorder, paving the way for better therapeutic options for affected families.